Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial (vol 374, pg 1503, 2009)

被引：0
|
作者：
Comi, G.
Martinelli, V
Rodegher, M.
机构：
来源：
LANCET | 2010年 / 375卷 / 9724期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1436 / 1436
页数：1
相关论文
共 50 条
  • [31] Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
    Ebers, GC
    Rice, G
    Lesaux, J
    Paty, D
    Oger, J
    Li, DKB
    Beall, S
    Devonshire, V
    Hashimoto, S
    Hooge, J
    Kastrukoff, L
    Krieger, C
    Mezei, M
    Seland, P
    Vorobeychi, G
    Morrison, W
    Nelson, J
    Freedman, MS
    Chrisie, S
    Nelson, R
    Rabinovitch, H
    Freedman, C
    Hartung, HP
    Rieckmann, P
    Archelos, J
    Jung, S
    Weilbach, F
    Flachenecke, P
    Sauer, J
    Hommes, O
    Jongen, P
    Brouwer, S
    McLeod, J
    Pollard, J
    Ng, R
    Sandberg-Wollheim, M
    Källén, K
    Nilsson, P
    Ekberg, R
    Lundgren, A
    Jadbäck, G
    Wikström, J
    Multanen, J
    Valjakka, M
    Carton, H
    Lissoir, F
    Declerq, I
    Vieren, M
    Peeters, E
    Dubois, B
    LANCET, 1998, 352 (9139): : 1498 - 1504
  • [32] A randomised, double-blind, placebo-controlled trial of duloxetine for the treatment of central neuropathic pain associated with multiple sclerosis
    Vollmer, T.
    Robinson, M.
    Risser, R.
    Malcolm, S. K.
    Carlson, J.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S476 - S477
  • [33] Safety and efficacy of thalidomide in patients with POEMS syndrome: a multicentre, randomised, double-blind, placebo-controlled trial
    Misawa, Sonoko
    Sato, Yasunori
    Katayama, Kanako
    Nagashima, Kengo
    Aoyagi, Reiko
    Sekiguchi, Yukari
    Sobue, Gen
    Koike, Haruki
    Yabe, Ichiro
    Sasaki, Hidenao
    Watanabe, Osamu
    Takashima, Hiroshi
    Nishizawa, Masatoyo
    Kawachi, Izumi
    Kusunoki, Susumu
    Mitsui, Yoshiyuki
    Kikuchi, Seiji
    Nakashima, Ichiro
    Ikeda, Shu-ichi
    Kohara, Nobuo
    Kanda, Takashi
    Kira, Jun-ichi
    Hanaoka, Hideki
    Kuwabara, Satoshi
    LANCET NEUROLOGY, 2016, 15 (11): : 1129 - 1137
  • [34] Randomised double-blind placebo-controlled study of interferon β-1a in relapsing-remitting multiple sclerosis (vol 352, pg 1498, 1998)
    Ebers, GC
    McDougall, A
    Frith, J
    LANCET, 1999, 353 (9153): : 678 - 678
  • [35] A randomised, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis
    Takehara, K.
    Ihn, H.
    Sato, S.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2013, 31 (02) : S151 - S156
  • [36] Evaluation of the effect of sildenafil on the microvascular blood flow in patients with systemic sclerosis: a randomised, double-blind, placebo-controlled study
    Andrigueti, F. V.
    Ebbing, P. C. C.
    Arismendi, M. I.
    Kayser, C.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2017, 35 (04) : S151 - S158
  • [37] GLANCE: A double-blind, randomised, placebo-controlled, parallel-group safety study of natalizumab (Antegren) in combination with glatiramer acetate (Copaxone) in subjects with relapsing-remitting multiple sclerosis
    Goodman, A
    Bar-Or, A
    Miller, A
    Miller, D
    Panzara, M
    Rossman, H
    Schmierer, K
    Toal, M
    JOURNAL OF NEUROLOGY, 2004, 251 : 176 - 177
  • [38] Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial
    Nourbakhsh, Bardia
    Revirajan, Nisha
    Morris, Bridget
    Cordano, Christian
    Creasman, Jennifer
    Manguinao, Michael
    Krysko, Kristen
    Rutatangwa, Alice
    Auvray, Caroline
    Aljarallah, Salman
    Jin, Chengshi
    Mowry, Ellen
    McCulloch, Charles
    Waubant, Emmanuelle
    LANCET NEUROLOGY, 2021, 20 (01): : 38 - 48
  • [39] Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial
    Kappos, Ludwig
    Arnold, Douglas L.
    Bar-Or, Amit
    Camm, John
    Derfuss, Tobias
    Kieseier, Bernd C.
    Sprenger, Till
    Greenough, Kristin
    Ni, Pingping
    Harada, Tomohiko
    LANCET NEUROLOGY, 2016, 15 (11): : 1148 - 1159
  • [40] Dalfampiridine improves cognitive impairment in multiple sclerosis (MS): results from a randomised, double-blind, placebo-controlled trial
    De Giglio, Laura
    De Luca, Francesca
    Gurreri, Flavia
    Ferrante, Ilaria
    Prosperini, Luca
    Quartuccio, Maria Esmeralda
    Borriello, Giovanna
    Gasperini, Claudio
    Pozzilli, Carlo
    NEUROLOGY, 2017, 88
12345